Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Pfizer And BioNTech Announced Topline Results From An Ongoing Phase 3 Trial Cohort Evaluating 30-µg Dose Of LP.8.1-adapted Monovalent Comirnaty 2025-2026 Formula, Demonstrating Robust Immune Response In Older Patients

Author: Benzinga Newsdesk | September 08, 2025 06:48am
  • Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the LP.8.1-adapted COVID-19 vaccine 2025-2026 Formula
  • First LP.8.1 sublineage clinical findings reinforce pre-clinical data supporting recent FDA approval of 2025-2026 Formula of Pfizer-BioNTech COVID-19 Vaccine
  • Companies have submitted these data to the FDA

Posted In: BNTX PFE

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist